Skip to content
An Initiative of AVAC In partnership with Access Bridge
Search
Back to News & Stories

PxWire Volume 16, Issue No. 3

27 August 2026

Check out the latest issue of PxWire here! And see key highlights below:

  • Significant challenges persist in the wake of cuts to PEPFAR funding and programs, as the ripple effects continue to be felt across the field and organizations grapple with how to maintain services with fewer resources.
  • Merck/MSD’s decision to provide generic manufacturing agreements for alimatravir (AMI) more than a year out from efficacy trial results is unprecedented—but not all advocacy demands were met.
  • The HIV research pipeline continues to evolve, especially around long-acting interventions, including promising results for a new weekly pill for HIV treatment.
  • Recent research has made combo bNAbs even more complicated, but the CAPRISA 012c study continues to deepen understanding of HIV and the immune system, and will continue to inform vaccine design, cure research and the next generation of prevention strategies.